Study S001513

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec / Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov record

Registration

Registration: NCT04952779
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 750
Start: 2021-06-02
Primary completion: 2024-12-15
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Xultophy® (insulin degludec/liraglutide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:1111-1211-7084

Registered primary outcomes

Incidence of Adverse Events (AEs) by preferred term [baseline (Visit1, 0 week) to 26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.